Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors.
Bioorg Med Chem Lett
; 21(12): 3788-93, 2011 Jun 15.
Article
em En
| MEDLINE
| ID: mdl-21561771
ABSTRACT
Anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is considered a promising therapeutic target for human cancers. We identified novel tetracyclic derivatives as potent ALK inhibitors. Among them, compound 27 showed strong cytotoxicity against KARPAS-299 with an IC(50) value of 21 nM and significant antitumor efficacy in ALK fusion-positive blood and solid cancer xenograft models in mice without body weight loss.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tetraciclinas
/
Receptores Proteína Tirosina Quinases
/
Descoberta de Drogas
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article